CLOs on the Move

Allos Therapeutics

www.allos.com

 
Allos Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing small molecule drugs for the treatment of cancer. The CompanyÍs lead product candidate, pralatrexate (PDX) an antifolate, is in Phase II trial in
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics. The Company`s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet.

Opexa Therapeutics

Opexa Therapeutics is a Spring, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RTD Company

RTD Company is a Andover, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rockland Immunochemicals

Rockland Immunochemicals is a Gilbertsville, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Invivyd

Invivyd is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd`s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications.